Hipolin Intrinsic Value
Hipolin (HIPOLIN) median intrinsic value is ₹24.94 from 6 valuation models (range ₹25–₹67), vs current price ₹83.12 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Hipolin stock price NSE .
HIPOLIN Valuation Methods Summary — DCF, Graham Number & P/E
Hipolin intrinsic value across 6 models vs current price ₹83.12 — upside/downside and value range per method. Browse Hipolin annual reports for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹24.94 | ₹19.95 - ₹29.93 | -70.0% | EPS: ₹0.04, Sector P/E: 25x |
| Book Value Method | asset | ₹66.67 | ₹60.00 - ₹73.34 | -19.8% | Book Value/Share: ₹26.67, P/B: 2.5x |
| Revenue Multiple Method | revenue | ₹60.00 | ₹54.00 - ₹66.00 | -27.8% | Revenue/Share: ₹40.00, P/S: 1.5x |
| PEG Ratio Method | growth | ₹24.94 | ₹22.45 - ₹27.43 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹24.94 | ₹22.45 - ₹27.43 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 18.5x |
| Graham Defensive Method | conservative | ₹24.94 | ₹22.45 - ₹27.43 | -70.0% | EPS: ₹0.04, BVPS: ₹26.67 |
HIPOLIN Intrinsic Value vs Market Price — All Valuation Models
Hipolin fair value range ₹25–₹67 vs current market price ₹83.12 across 6 valuation models. Compare with Hipolin valuation methods to assess whether the stock is under or overvalued.
HIPOLIN Intrinsic Value Analysis — Undervalued or Overvalued?
Hipolin median intrinsic value ₹24.94, current price ₹83.12 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of HIPOLIN?
Based on our comprehensive analysis using 6 different valuation methods, the estimated intrinsic value of Hipolin (HIPOLIN) is ₹24.94 (median value). With the current market price of ₹83.12, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹24.94 to ₹66.67, indicating ₹24.94 - ₹66.67.
Is HIPOLIN undervalued or overvalued?
Based on our multi-method analysis, Hipolin (HIPOLIN) appears to be trading above calculated value by approximately 70.0%.
HIPOLIN Financial Health — Key Ratios vs Industry Benchmarks
Hipolin financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
HIPOLIN Cash Flow Quality — Operating & Free Cash Flow
Hipolin operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |